A study published this week presents evidence that – through mechanisms unknown at this point – antibodies appear to be able to enter cancer cells, bind to intracellular proteins and, ultimately, kill the cells. Read More
Danish biopharmaceutical company Orphazyme ApS raised €14 million (US$19.7 million) in a Series A financing to move its lead program, Orph-001, into the clinic. The company, based in Copenhagen, is pursuing technology related to molecular chaperone heat-shock protein 70 (Hsp70) to treat disorders known as lysosomal storage diseases (LSD) – a family of more than 45 often-fatal genetic disorders with few existing treatment options. Read More
ISTA Pharmaceuticals Inc., of Irvine, Calif., said a paper published in RETINA, The Journal of Retinal and Vitreous Diseases, of a pilot study suggested that the topical nonsteroidal anti-inflammatory eye drop Xibrom (bromfenac ophthalmic solution) administered twice daily might have an additive effect when used with intravitreal Lucentis (ranibizumab injection, Roche AG) in reducing retinal thickness in neovascular age-related macular degeneration. Read More
Pluristem Therapeutics Inc., of Haifa, Israel, said animal studies suggested that its PLacental eXpanded (PLX) cells are potentially effective in treating life-threatening hematopoietic complications associated with acute radiation syndrome. Read More
LONDON – Antibody engineering specialist F-Star GmbH landed a second partner for its novel antibody formats, signing up Merck Serono SA in an inflammatory disease deal with a headline value of €492 million (US$691.1 million). Read More
When the planes crashed into the World Trade Center 10 years ago, the U.S. woke to a "new normal" – a frightening awareness of the nation's vulnerability. Read More
